MedTrace Logo

Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma

NCT06464380 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-09-23

No results posted yet for this study

Summary

Saffron has recently gained considerable interest for its capacity to interfere with cancer at initiation and promotion stages as well as for cancer treatment. Although saffron and its constituents have been shown to have antitumorigenic and proapoptotic activities in different cancer cell lines.

The aim of the current investigation is to identify the anti-cancer potentiality of saffron on hepatocellular carcinoma patients.

Conditions

Interventions

DIETARY_SUPPLEMENT

Saffranal

HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.

DIETARY_SUPPLEMENT

Placebo

HCC patients will receive Placebo in dose of once per day for six months.

Sponsors & Collaborators

  • Mohamed, Ahmed A., M.D.

    collaborator INDIV

  • Amr Amin College of Medicine, University of Sharjah, Sharjah 27272, UAE.

    collaborator UNKNOWN

  • Ahmed Cordie Endemic Medicine department, Cairo University Hospitals.

    collaborator UNKNOWN

  • Nouran Mohamed Endemic Medicine department, Cairo University Hospitals.

    collaborator UNKNOWN

  • Gamal Esmat Faculty of Biotechnology, Misr University for Science and Technology, Giza, Egypt.

    collaborator UNKNOWN

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-30
Primary Completion
2025-05-01
Completion
2025-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06464380 on ClinicalTrials.gov